Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial

ABSTRACT: Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of performing and obtaining data from a few key molecular assays. Patients with metastatic colorectal cancer, non-small cell lung cancer or melanoma will be enrolled. Biopsie from metastatic lesions will be performed. A targeted cancer gene screen assay will be performed using DNA sequencing. Results will be discussed during a molecular screening tumor board.

DISEASE(S): Metastatic Melanoma,Colorectal Cancer Metastatic,Metastatic Non-small Cell Lung Carcinoma,Carcinoma, Non-small-cell Lung

PROVIDER: 2150838 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Transcriptome analysis by RNA-seq of ovarian cancer derived from the Cancer Institute Hospital of Japanese Foundation for Cancer Research.

Project description:We performed the RNA-seq experiments for mRNA of ovarian cancer tissue. Raw data not provided. Institutional Review Board (IRB) does not allow submitters to disclose raw data to the public

2017-08-31 | GSE101948 | GEO

Metastatic Adult Pancreatoblastoma: Multimodal Treatment and Molecular Characterization of a Very Rare Disease (NCT MASTER)

Project description:Pancreatoblastoma is a rare malignant tumor that occurs predominantly in children. We identified four adult patients with metastasizing pancreatoblastoma at a high-volume German university cancer center which were treated with multimodal therapies between 2013 and 2018. In three cases, we performed a comprehensive molecular analysis that included whole-genome sequencing (WGS) or whole-exome sequencing (WES); transcriptome sequencing was performed in two cases, respectively. Subsequent recommendations of molecularly stratified treatment options were discussed within a dedicated molecular tumor board (MTB) embedded in a precision oncology program (NCT MASTER).

| EGAS00001004157 | EGA

Transcriptomic Profiling of Posterior Polymorphous Corneal Dystrophy

Project description:To investigate the molecular basis of posterior polymorphous corneal dystrophy (PPCD) by examining the transcriptome in affected individuals and the effect of decreased ZEB1 expression on corneal endothelial gene expression.

2017-08-17 | GSE90489 | GEO

Gene Expression Profiling of Oral Squamous Cell Carcinoma

Project description:Gene Expression Profiling of Oral Squamous Cell Carcinoma (OSCC) was performed to delineate candidate genes clusters with potential to distinguish normal and tumor tissue from oral cavity. All tissue samples were collected after obtaining written informed consent.

2011-10-30 | GSE23558 | GEO

Gene expression analysis of Human CD34+ cells derived from bone marrow, mobilized peripheral blood, umbillial cord blood using Agilent Whole Human Genome Oligo Microarrays (one-color)

Project description:In order to identify genes associated with the engraftment potential of human hematopoietic stem cells, we have employed whole genome microarray expression profiling of G0 and G1 phase CD34+ cells derived from bone marrow, mobilized peripheral blood, and umbilical cord blood. Samples were collected from healthy adult volunteers after obtaining informed consent according to the guidelines of the Investigational Review Board of Indiana University School of Medicine. CD34+ cells were selected and fractionated into G0 and G1 phases of cell cycle on a flow cytometer. Purity of sorted cells was further confirmed by qRT-PCR by measuring the relative expression of Ki67. Sorted cells were subjeccted to microarray analysis.

2010-09-20 | GSE24231 | GEO

Gene expression profiling of human NK cells

Project description:To investigate novel molecular signatures and transcriptional regulators of immature and mature human NK cells, we performed whole-genome microarray analysis on dNK cells (CD3−CD56+), cNK cells (CD3−CD56+), pNK cells (CD3−CD56+), CD56+ T cells (CD3+CD56+) and T cells (CD3+CD56−). dNK cells were purified from first-trimester deciduas. cNK cells were puriﬁed from cord-blood mononuclear cells. pNK, CD56+ T and T cells were purified from adult peripheral blood mononuclear cells. Samples were collected from healthy adult donors after obtaining informed consent according to the Ethics Committee of the University of Science & Technology of China.

2013-02-10 | GSE24268 | GEO

Gene Expression Profiling of Airway and Distal Lung Fibroblasts

Project description:Fresh lung tissue specimens from distal lungs (n=3) and airways (n=3) were obtained through bronchoscopy, and primary fibroblasts were isolated and cultured. IRB approval was obtained from the University of Pittsburgh Institutional Review Board.

2010-02-20 | GSE15359 | GEO

Transcriptional profiling of mESC-derived tendon and fibrocartilage cell fate switch [scRNA-seq]

Project description:We report a high-efficiency differentiation protocol to tendon and fibrocartilage perform molecular profiling of tendon and fibrocartilage fatse in relation to developmetnal in vivo analogues. We also the molecular induction of tendon and fibrocartilage by examining fate dependent and independent gene modules

2021-06-11 | GSE154525 | GEO

Gene Expression Profiling of Human High-Grade Serous Ovarian Tumor Samples

Project description:The goal of the study was to further delineate the molecular signatures associated with high-grade serous ovarian cancer in order to develop validated clinically useful prognostic signatures with the potential to guide therapy decisions. Fresh frozen samples were prospectively collected from a series of 174 consecutive women with high-grade serous ovarian, primary peritonial, or fallopian tube cancer who underwent surgery by a gynecologic oncologist at Mayo Clinic betweern 1994 and 2005. All patients received postoperative chemotherapy with a platinum agent, and 75% received a taxane. All patients signed an Institutional Review Board approved consent for bio-banking, clinical data extraction and molecular analysis. Median follow-up time was 35 months (range, 1-202 months). Fourteen patients (8%) were included in the TCGA study.

2015-01-07 | GSE53963 | GEO

On-board Preconcentration Microchip Capillary Electrophoresis Based TMT-PRM-LIVE for High-throughput Selectivity Profiling of Deubiquitinase Inhibitors

Project description:On-board Preconcentration Microchip Capillary Electrophoresis Based TMT-PRM-LIVE for High-throughput Selectivity Profiling of Deubiquitinase Inhibitors

2022-03-24 | MSV000089122 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data